UB Paderborn / Katalog / Suche / in CDI

Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents

Journal of medicinal chemistry, 2017-05, Vol.60 (9), p.3755-3775

2017

Volltextzugriff (PDF)

Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases

Journal of medicinal chemistry, 2024-05, Vol.67 (10), p.8077-8098

2024

Volltextzugriff (PDF)

Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies

Journal of medicinal chemistry, 2023-03, Vol.66 (6), p.4179-4196

2023

Volltextzugriff (PDF)

Discovery of a Potent, Selective T‑type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies

Journal of medicinal chemistry, 2017-12, Vol.60 (23), p.9769-9789

2017

Volltextzugriff (PDF)

Synthesis and Characterization of Tetrahydropyran-Based Bacterial Topoisomerase Inhibitors with Antibacterial Activity against Gram-Negative Bacteria

Journal of medicinal chemistry, 2017-05, Vol.60 (9), p.3776-3794

2017

Volltextzugriff (PDF)

Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T‑Type Calcium Channel Blockers

Journal of medicinal chemistry, 2016-09, Vol.59 (18), p.8398-8411

2016

Volltextzugriff (PDF)

Discovery and evaluation of Cav3.2-selective T-type calcium channel blockers

Bioorganic & medicinal chemistry letters, 2017-12, Vol.27 (23), p.5326-5331

2017

Volltextzugriff (PDF)

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Journal of visualized experiments, 2018-10 (140)

2018

Volltextzugriff (PDF)

Discovery and evaluation of Cav3.1-selective T-type calcium channel blockers

Bioorganic & medicinal chemistry letters, 2017-12, Vol.27 (23), p.5322-5325

2017

Volltextzugriff (PDF)

Discovery and evaluation of Ca v 3.1-selective T-type calcium channel blockers

Bioorganic & medicinal chemistry letters, 2017-12, Vol.27 (23), p.5322-5325

2017

Volltextzugriff (PDF)

Discovery and evaluation of Ca v 3.2-selective T-type calcium channel blockers

Bioorganic & medicinal chemistry letters, 2017-12, Vol.27 (23), p.5326-5331

2017

Volltextzugriff (PDF)

A uniquely efficacious type of CFTR corrector with complementary mode of action

Science advances, 2024-03, Vol.10 (9), p.eadk1814-eadk1814

2024

Volltextzugriff (PDF)

Novel Tetrahydropyran-Based Bacterial Topoisomerase Inhibitors with Potent Anti-Gram Positive Activity and Improved Safety Profile

Journal of medicinal chemistry, 2015-01, Vol.58 (2), p.927-942

2015

Volltextzugriff (PDF)

Nomenclature of Voltage-Gated Calcium Channels

Neuron (Cambridge, Mass.), 2000-03, Vol.25 (3), p.533-535

2000

Volltextzugriff (PDF)

Cardiomyocytes Derived from Human Induced Pluripotent Stem Cells: An In-Vitro Model to Predict Cardiac Effects of Drugs

Journal of biomedical science and engineering, 2017, Vol.10 (11), p.527-549

2017

Volltextzugriff (PDF)

Nodulisporic Acid Opens Insect Glutamate-Gated Chloride Channels: Identification of a New High Affinity Modulator

Biochemistry (Easton), 2000-05, Vol.39 (18), p.5543-5554

2000

Volltextzugriff (PDF)

Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker

Journal of hypertension, 1997-12, Vol.15 Suppl 5 (5), p.S17-S26

1997

Volltextzugriff (PDF)

Evaluation of the rabbit purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans

Drug safety, 2006-01, Vol.29 (3), p.237-254

2006

Volltextzugriff (PDF)

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Journal of visualized experiments, 2018-10 (140)

2018

Volltextzugriff (PDF)

Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells

The Journal of pharmacology and experimental therapeutics, 1998-12, Vol.287 (3), p.824

1998

Volltextzugriff (PDF)

Lucerastat, an iminosugar for substrate reduction therapy in Fabry disease: preclinical evidence

Molecular genetics and metabolism, 2017-01, Vol.120 (1-2), p.S139-S140

2017

Volltextzugriff (PDF)

Pharmacological properties of Ca v 3.2, a low voltage-activated Ca 2+ channel cloned from human heart

Naunyn-Schmiedeberg's archives of pharmacology, 2000-05, Vol.361 (6), p.590-599

2000

Volltextzugriff (PDF)

Type III .omega.-Agatoxins: A Family of Probes for Similar Binding Sites on L- and N-Type Calcium Channels

Biochemistry (Easton), 1994-05, Vol.33 (17), p.5098-5108

1994

Volltextzugriff (PDF)

Low-voltage-activated T-type Ca2+ channels

Trends in pharmacological sciences, 1997-02, Vol.18 (2), p.37-42

1997

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents

Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases

Milestones to the Discovery of T-type Calcium Channel Blockers for the Treatment of Generalized Epilepsies

Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies

Discovery of a Potent, Selective T‑type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies

Synthesis and Characterization of Tetrahydropyran-Based Bacterial Topoisomerase Inhibitors with Antibacterial Activity against Gram-Negative Bacteria

Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T‑Type Calcium Channel Blockers

Discovery and evaluation of Cav3.2-selective T-type calcium channel blockers

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Discovery and evaluation of Cav3.1-selective T-type calcium channel blockers

Discovery and evaluation of Ca v 3.1-selective T-type calcium channel blockers

Discovery and evaluation of Ca v 3.2-selective T-type calcium channel blockers

A uniquely efficacious type of CFTR corrector with complementary mode of action

Novel Tetrahydropyran-Based Bacterial Topoisomerase Inhibitors with Potent Anti-Gram Positive Activity and Improved Safety Profile

Nomenclature of Voltage-Gated Calcium Channels

Cardiomyocytes Derived from Human Induced Pluripotent Stem Cells: An In-Vitro Model to Predict Cardiac Effects of Drugs

Nodulisporic Acid Opens Insect Glutamate-Gated Chloride Channels: Identification of a New High Affinity Modulator

Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker

Evaluation of the rabbit purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells

Lucerastat, an iminosugar for substrate reduction therapy in Fabry disease: preclinical evidence

Pharmacological properties of Ca v 3.2, a low voltage-activated Ca 2+ channel cloned from human heart

Type III .omega.-Agatoxins: A Family of Probes for Similar Binding Sites on L- and N-Type Calcium Channels

Low-voltage-activated T-type Ca2+ channels

Suchergebnisse filtern